Health Law Investor Series: Vertical Mergers: The Latest Casualty of Biden’s Antitrust Agenda



Date & Time

Start Date: 02/16/2022
Start Time: 1:00 pm
End Time: 1:45 pm EST


For years, it was highly unusual for the Department of Justice and the Federal Trade Commission to challenge so-called “vertical” mergers, where the merging parties provide different supply chain functions for a common good or service. Indeed, neither agency has successfully litigated a vertical merger case since the Nixon administration. In the past year, however, the FTC has essentially killed two vertical mergers: Illumina/Grail and Nvidia/Arm and is litigating a third, Lockheed Martin/Aerojet Rocketdyne. Please join us as we dig into these three transactions to see what lessons can be learned and ask what types of deals might be the next targets of the antitrust enforcers.

Cozen O’Connor’s Health Law Investor Series is a monthly discussion on issues facing the health care industry and those who invest in the industry.

To view the webinar slides, click here.


Share on LinkedIn


Jonathan M. Grossman

Co-Chair, Antitrust

(202) 912-4866

Related Practices